Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

GEO accession GSE157492 is currently private and is scheduled to be released on Dec 31, 2025.

ABSTRACT: GEO accession GSE157492 is currently private and is scheduled to be released on Dec 31, 2025.

PROVIDER: PRJNA661471 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Tenofovir and dolutegravir reduce human T-cell leukemia virus 1 transmission and de novo viral spread in vivo

Project description:Human T-leukemia virus 1 (HTLV-1) is an oncogenic retrovirus with no available curative therapy. In-vitro data suggests HTLV-1 may be susceptible to certain HIV-1 antiretroviral compounds but their value, if any, in the context of a clinically-relevant transmission model is unknown. We addressed this knowledge gap by investigating the efficacy of the anti-retroviral compounds, tenofovir and dolutegravir, in preventing HTLV-1 transmission and infection in a humanised mouse model of HTLV-1 subtype c (HTLV-1c) infection, the first of its kind. Characterisation of this model revealed that HTLV-1c and HTLV-1 subtype a (HTLV-1a) showed subtle differences in natural history of disease but not as striking as the differences observed clinically, indicating additional host and environmental contributors to human disease. Single cell RNA sequencing of CD4+ T cell VDJ transcripts revealed poly- and oligoclonal expansion of HTLV-1c-infected CD4+ T cells. We show that tenofovir significantly reduces HTLV-1 transmission in vivo at clinically relevant doses when administered as pre-exposure prophylaxis. Further, tenofovir and dolutegravir combination significantly attenuates viral spread and disease progression during early infection. Our data support the use of tenofovir and dolutegravir against HTLV-1 transmission and early infection. Routine use of these drugs as effective prophylactic agents against HIV-1 infection will facilitate their rapid translation to HTLV-1 clinical trials.

2025-12-31 | GSE157492 | GEO

Understanding and reversing mammary tumour-driven reprogramming of myelopoieisis to reduce metastatic spread [ATAC-seq]

Project description:Tumour-induced systemic accumulation and polarisation of neutrophils to an immunosuppressive phenotype is a potent driver of metastasis formation. Yet how mammary tumours reprogram granulopoiesis at the molecular level and when tumour imprinting occurs during neutrophil development remains underexplored. Here we combined single cell, chromatin and functional analyses to unravel the tumour-driven reprogramming of granulopoiesis, along with intervention studies aimed at reversing this process. We observe that mammary tumours accelerate commitment to the neutrophil lineage at the expense of lymphopoiesis and erythropoiesis without stimulating the development of a novel myeloid lineage. Moreover, tumour-directed immunosuppressive imprinting of neutrophils starts early in haematopoiesis. Treatment with anti-IL-1β normalised tumour-induced granulopoiesis, reduced neutrophil production of T cell suppressive superoxides and mitigated metastatic spread. Together, these data provide molecular insights into the aberrant tumour-driven neutrophil differentiation pathway leading to metastasis-promoting chronic inflammation and how it can be reversed to reduce metastatic spread.

2025-04-08 | GSE264085 | GEO

Understanding and reversing mammary tumour-driven reprogramming of myelopoieisis to reduce metastatic spread [scRNA-seq]

2025-04-08 | GSE264087 | GEO

Understanding and reversing mammary tumour-driven reprogramming of myelopoieisis to reduce metastatic spread [bulk RNA-seq]

2025-04-08 | GSE264086 | GEO

Understanding and reversing mammary tumour-driven reprogramming of myelopoieisis to reduce metastatic spread

Project description:Understanding and reversing mammary tumour-driven reprogramming of myelopoieisis to reduce metastatic spread

| PRJNA1100962 | ENA

Ex vivo effects of Tenofovir on four vaginal epithelial cell lines

Project description:In MTN-007, a phase 1, randomized, double-blinded rectal microbicide trial, we used systems genomics/proteomics to determine the effect of tenofovir 1% gel, nonoxynol-9 2% gel, placebo gel or no treatment on rectal biopsies taken at baseline, after one application or after seven daily applications (15 subjects/arm). Experiments were repeated using primary vaginal epithelial cells from four healthy women. 36 Arrays (3 primary vaginal epithelial cell lines from healthy women donors, cultured with or without 50uM or 500 uM Tenofovir for 1,4,7, or 14 days per donor cell line. A no treatment, culture media only control was included for each donor cell line and for each time point.

2015-02-23 | E-GEOD-57026 | biostudies-arrayexpress

The antiretroviral drugs, dolutegravir, maraviroc and ritonavir-boosted atazanavir, affect inflammation and insulin sensitivity in human coronary endothelial cells through different pathways

Project description:The antiretroviral drugs, dolutegravir, maraviroc and ritonavir-boosted atazanavir, affect inflammation and insulin sensitivity in human coronary endothelial cells through different pathways.

2020-02-05 | GSE137247 | GEO

Understanding and reversing mammary tumour-driven reprogramming of myelopoieisis to reduce metastatic spread [ATAC-seq]

Project description:Understanding and reversing mammary tumour-driven reprogramming of myelopoieisis to reduce metastatic spread [ATAC-seq]

| PRJNA1100963 | ENA

Understanding and reversing mammary tumour-driven reprogramming of myelopoieisis to reduce metastatic spread [scRNA-seq]

Project description:Understanding and reversing mammary tumour-driven reprogramming of myelopoieisis to reduce metastatic spread [scRNA-seq]

| PRJNA1100977 | ENA

Understanding and reversing mammary tumour-driven reprogramming of myelopoieisis to reduce metastatic spread [bulk RNA-seq]

Project description:Understanding and reversing mammary tumour-driven reprogramming of myelopoieisis to reduce metastatic spread [bulk RNA-seq]

| PRJNA1100970 | ENA